COMPANY
Clinical Phase 2
Profile checked Oct 10, 2026
Keywords: Cognitive Impairment Schizophrenia Cognitive Impairment Associated With Schizophrenia RL-007 (Inidascamine) RL-007
Timeline
- Trial start Phase 2: A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) source ↗
- Trial start Phase 2: Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05686239 | A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) | Phase 2 | Completed | Dec 8, 2022 | Apr 9, 2025 (actual) |
| NCT04822883 | Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia | Phase 2 | Completed | Apr 26, 2021 | Oct 28, 2021 (actual) |
